Newswire (Published: Tuesday, February 28, 2017, Received: Friday, February 24, 2017, 11:37:03 AM CST)

Word Count: 592

New Prostate Cancer Study Findings Recently Were Reported by Researchers at Johns Hopkins University School of Medicine (Prostate Health Index density improves detection of clinically significant prostate cancer)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating from Baltimore, Maryland, by NewsRx correspondents, research stated, "To explore the utility of Prostate Health Index (PHI) density for the detection of clinically significant prostate cancer (PCa) in a contemporary cohort of men presenting for diagnostic evaluation of PCa. The study cohort included patients with elevated prostate-specific antigen (PSA; >2 ng/mL) and negative digital rectal examination who underwent PHI testing and prostate biopsy at our institution in 2015."

Funders for this research include DOD PRTA Award, Prostate Cancer Foundation, Patrick C. Walsh Investigator Grant (see also Oncology - Prostate Cancer).

Our news editors obtained a quote from the research from the Johns Hopkins University School of Medicine, "Serum markers were prospectively measured per standard clinical pathway. PHI was calculated as ([{-2}proPSA/free PSA] ? [PSA] ), and density calculations were performed using prostate volume as determined by transrectal ultrasonography. Logistic regression was used to assess the ability of serum markers to predict clinically significant PCa, defined as any Gleason score greater than or equal to7 cancer or Gleason score 6 cancer in >2 cores or >50% of any positive core. Of 118 men with PHI testing who underwent biopsy, 47 (39.8%) were found to have clinically significant PCa on biopsy. The median (interquartile range [IQR]) PHI density was 0.70 (0.43-1.21), and was 0.53 (0.36-0.75) in men with negative biopsy or clinically insignificant PCa and 1.21 (0.74-1.88) in men with clinically significant PCa (p <0.001). Clinically significant PCa was detected in 3.6% of men in the first quartile of PHI density (<0.43), 36.7% of men in the IQR of PHI density (0.43-1.21), and 80.0% of men with PHI density >1.21 (p <0.001). Using a threshold of 0.43, PHI density was 97.9% sensitive and 38.0% specific for clinically significant PCa, and 100% sensitive for Gleason score greater than or equal to7 disease. Compared with PSA (area under the curve [AUC] 0.52), PSA density (AUC 0.70), %free PSA (AUC 0.75), the product of %free PSA and prostate volume (AUC 0.79), and PHI (AUC 0.76), PHI density had the highest discriminative ability for clinically significant PCa (AUC 0.84)."

According to the news editors, the research concluded: "Based on the present prospective single-centre experience, PHI density could be used to avoid 38% of unnecessary biopsies, while failing to detect only 2% of clinically significant cancers."

For more information on this research see: Prostate Health Index density improves detection of clinically significant prostate cancer. Bju International, 2017;():. (Wiley-Blackwell -; Bju International -

The news editors report that additional information may be obtained by contacting J.J. Tosoian, Dept. of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Additional authors for this research include S.C. Druskin, D. Andreas, P. Mullane, M. Chappidi, S. Joo, K. Ghabili, M. Mamawala, J. Agostino, H.B. Carter, A.W. Partin, L.J. Sokoll and A.E Ross.

Keywords for this news article include: Maryland, Oncology, Baltimore, United States, Prostate Cancer, Prostatic Neoplasms, Enzymes and Coenzymes, North and Central America, Diagnostics and Screening, Prostate Specific Antigen.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Central America
North America
United States
Baltimore County


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Medical Research
      Medical Specialties and Practices